2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2a adenosine receptor antagonists

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4449-4455

  Mantri, Monica ^a   De Graaf, Olivier ^a   Van Veldhoven, Jacobus ^a   Göblyös, Aniko ^a   Von Frijtag Drabbe Künzel, Jacobien K ^a   Mulder Krieger, Thea ^a   Link, Regina ^a   De Vries, Henk ^a   Beukers, Margot W ^a   Brussee, Johannes ^a   Ijzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 AMINO 4 THIOPHEN 2 YL 6 FURAN 2 YL NICOTINONITRILE; 2 AMINO 4,6 DIFURAN 2 YL NICOTINONITRILE; 2 AMINO NICOTINONITRILE DERIVATIVE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR A2A ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; CYCLIC AMP; FURAN DERIVATIVE; LUF 6050; LUF 6080; PHENYL GROUP; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL STRAIN HEK293; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EMBRYO; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMINES; ANIMALS; CELL LINE; CRICETINAE; CYCLIC AMP; FURANS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NICOTINIC ACIDS; NITRILES; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49449100234     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701594y     Document Type: Article

References (31)

1. 2A receptors: an overview. Brain Res. Rev. 1999, 31, 65-82.
2. 2A receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2005, 105, 267-310.
3. Jacobson, K. A.; Gao, Z.-G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discovery 2006, 5, 247-264.
4. 2A Adenosine Receptor Antagonists with 8-Styrylxanthine Structure: Potential Drug for Parkinson's Disease. J. Org. Chem. 2004, 69, 3308-3318.
5. Ongini, E.; Dionisotti, S.; Gessi, S.; Irenius, E.; Fredholm, B. B. Comparison of CGS15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 1999, 359, 7-10.
6. 2A) antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 1333-1336.
7. 2A receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 4809-4813.
8. 2A antagonists. Part 1. Bioorg. Med. Chem. Lett. 2005, 15, 3670-3674.
9. 2A antagonists'. The successful reduction of hERG activity. Part 2. Bioorg. Med. Chem. Lett. 2005, 15, 3675-3678.
10. 2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 511-515.
11. 2A Receptor Antagonists. J. Med. Chem. 2004, 47, 6218-6229.
12. 2A Adenosine Receptor Antagonists. Bioorg. Med. Chem. 2003, 11, 5509-5518.
13. 2A receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 817-821.
14. 3 Adenosine Receptors Antagonists. J. Med. Chem. 2003, 46, 1229-1241.
15. 2A Adenosine Receptor Antagonists: A Study on the Importance of Modifications at the Side Chain on the Activity and Solubility. J. Med. Chem. 2002, 45, 115-126.
16. 2a receptor antagonists: comparison of three core heterocycles. Bioorg. Med. Chem. Lett. 2004, 14, 4831-4834.
17. 2A receptor antagonists for the treatment of Parkinson's disease. Neurology 2003, 61, 101-106.
18. 2A Adenosine Receptor Antagonists. Design, Synthesis, and Pharmacological Characterization. J. Med. Chem. 2005, 48, 6887-6896.
19. 2A receptor antagonists. Naunyn-Schmiedebergs Arch. Pharmacol. 2007, 375, 133-144.
20. 2A antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 1659-1662.
21. Spartan '04; Wavefunction Inc.: Irvine, CA, 2005.
22. 2B adenosine receptor antagonists. J. Chem. Inf. Model. 2007, 47, 613-625.
23. 2A antagonists using database mining and molecular similarity approaches. Bioorg. Med. Chem. Lett. 2006, 16, 5993-5997.
24. Murata, T.; Shimada, M.; Sakakibara, S.; Yoshino, T.; Kadono, H.; Masuda, T.; Shimazaki, M.; Shintani, T.; Fuchikami, K.; Sakai, K.; Takeshita, H. I. K.; Niki, T.; Umeda, M.; Bacon, K. B.; Zeigelbauer, K. B.; Lowinger, T. B. Discovery of Novel and Selective Ikk-β Serine-Threonine Protein Kinase Inhibitors Part 1. Bioorg. Med. Chem. 2003, 13, 913-918.
25. Kambe, S.; Saito, K. A Simple Method for the Preparation of 2-Amino-4-Aryl-3-Cyanopyridines by the Condensation of Malononitrile with Aromatic Aldehydes and Alkyl Ketones in the Presence of Ammonium Acetate. Synthesis 1980, 6, 366-368.
26. Cowart, M.; Lee, C.-H.; Gfesser, G. A.; Bayburt, E. K.; Bhagwat, S. S.; Stewart, A. O.; Yu, H.; Kohlhaas, K. L.; McGaraughty, S.; Wismer, C. T.; Mikusa, J.; Zhu, C.; Alexander, K. M.; Jarvis, M. F.; Kowaluk, E. A. Structure-Activity Studies of 5-Substituted Pyridopyrimidines as Adenosine Kinase Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 83-86.
27. Topliss, J. G. Utilization of Operational Schemes for Analog Synthesis in Drug Design. J. Med. Chem. 1972, 15, 1006-1011.
28. Anderson, D. R.; Stehle, N. W.; Kolodziej, S. A.; Reinhard, E. J. Preparation of aminocyanopyridines as inhibitors of mitogen activated protein kinase-activated protein kinase-2 for treating TNFα mediated diseases. WO 2004/055015 A1, 2004.
29. Lameijer, E. W.; Kok, J. N.; Back, T; IJzerman, A. P. The Molecule Evoluator. An interactive evolutionary algorithm for the design of drug-like molecules. J. Chem. Inf. Model. 2006, 46, 545-552.
30. Lameijer, E. W.; Tromp, R. A.; Spanjersberg, R. F.; Brussee, J.; IJzerman, A. P. Designing active template molecules by combining computational de novo design and human chemist's expertise. J. Med. Chem. 2007, 50, 1925-1932.
31. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.